Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention
- PMID: 15230290
- DOI: 10.1191/0961203303lu1024oa
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention
Abstract
Systemic lupus erythematosus (SLE) is an autoantibody and immune complex mediated disease. However, it is the ensuing inflammatory process that leads to irreversible organ damage. In fact several murine models of SLE suggest that this inflammatory organ damage can be prevented even in the presence of autoantibodies. Given data from experimental models as well as from patients, proinflammatory cytokines including tumour necrosis factor (TNF) alpha apparently play a significant role in the inflammatory process, but may have immunoregulatory functions at the same time. Therefore, anti-TNF alpha therapy may constitute an interesting candidate approach for treating SLE inflammatory organ disease, but potentially at the cost of increased autoantibody formation. Clinical trials will be required to answer whether TNF alpha blockade fulfils this hope with an acceptable safety profile. Interferon (IFN)-gamma, interleukin (IL)-18, IL-6 and possibly IL-1 are increased in SLE and likewise involved in the inflammatory process. Specific therapeutic agents for blocking these cytokines should be available in the near future.
Similar articles
-
BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.Cytokine. 2019 Feb;114:115-127. doi: 10.1016/j.cyto.2018.11.008. Epub 2018 Nov 19. Cytokine. 2019. PMID: 30467093
-
Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?Semin Arthritis Rheum. 2004 Jun;33(6):404-13. doi: 10.1016/j.semarthrit.2003.11.002. Semin Arthritis Rheum. 2004. PMID: 15190525
-
Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity.Cytokine. 2006 Aug;35(3-4):148-53. doi: 10.1016/j.cyto.2006.07.023. Epub 2006 Oct 5. Cytokine. 2006. PMID: 17027280
-
Cytokine expression in lupus kidneys.Lupus. 2005;14(1):13-8. doi: 10.1191/0961203305lu2053oa. Lupus. 2005. PMID: 15732282 Review.
-
Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.Int J Mol Sci. 2021 Oct 20;22(21):11327. doi: 10.3390/ijms222111327. Int J Mol Sci. 2021. PMID: 34768756 Free PMC article. Review.
Cited by
-
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.BMC Med. 2015 Feb 6;13:28. doi: 10.1186/s12916-014-0259-2. BMC Med. 2015. PMID: 25856766 Free PMC article. Review.
-
The Network of Inflammatory Mechanisms in Lupus Nephritis.Front Med (Lausanne). 2020 Nov 6;7:591724. doi: 10.3389/fmed.2020.591724. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33240910 Free PMC article. Review.
-
Concentrated fish oil (Lovaza(R)) extends lifespan and attenuates kidney disease in lupus-prone short-lived (NZBxNZW)F1 mice.Exp Biol Med (Maywood). 2013 Jun;238(6):610-22. doi: 10.1177/1535370213489485. Exp Biol Med (Maywood). 2013. PMID: 23918873 Free PMC article.
-
Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus.J Rheumatol. 2020 Sep 1;47(9):1359-1365. doi: 10.3899/jrheum.190502. Epub 2019 Nov 1. J Rheumatol. 2020. PMID: 31676703 Free PMC article.
-
Anti-TNF-alpha therapies in systemic lupus erythematosus.J Biomed Biotechnol. 2010;2010:465898. doi: 10.1155/2010/465898. Epub 2010 Jun 22. J Biomed Biotechnol. 2010. PMID: 20625488 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous